

STRATEGIES TO MAXIMIZE RESPONSE RATES AND OUTCOMES IN MULTIPLE MYELOMA



Release date: February 2011

Expiration date: February 29, 2012

Estimated time to complete activity: 2.5 hours

Jointly sponsored by Curatio CME Institute, the Multiple Myeloma Research Foundation, and Penn State College of Medicine.

Support for this activity has been provided through educational grants from Bristol-Myers Squibb, Celgene, Centocor Ortho Biotech, Lilly, Millennium: The Takeda Oncology Company, Novartis, and Onyx Pharmaceuticals.

This CME-certified Web-based enduring activity is based on information presented at a satellite symposium held on Friday, December 3, 2010 in Orlando, Florida during a major Hematology congress.

Hardware/Software Requirements

- Javascript-enabled browser
- Active Internet connection
- Adobe Acrobat Reader

Activity Overview

The outcome for patients with multiple myeloma has dramatically changed with the use of novel therapies such as thalidomide, lenalidomide, and bortezomib. Not only have these agents improved rates of responses—in particular, complete responses—but they have also improved overall survival. The addition of these new agents to the treatment paradigm also has implications on risk; much of what is currently understood about the association of multiple myeloma and poor outcomes is derived from experience with conventional treatment modalities (ie, chemotherapy and autologous stem cell transplantation [ASCT]) and may be becoming less clinically relevant. Using a case-based format, this activity addresses key issues currently facing clinicians who manage patients with multiple myeloma and provides guidance on the application of recent clinical trial data in making individualized, patient-specific treatment decisions.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care professionals involved in the care of patients with multiple myeloma.

Learning Objectives

At the conclusion of this activity, participants should be able to:

- Interpret the latest clinical trial data and incorporate current treatment advances to achieve best possible care of patients with multiple myeloma
- Utilize cytogenetics, fluorescence in situ hybridization (FISH), and gene expression profiling to define patient prognosis and risk stratification

Podcast available at curatiocme.com

- Outline a treatment plan to achieve durable complete response and extend survival in high-risk and standard-risk myeloma patients
- Implement evidence-based strategies to prolong the duration of response in patients with multiple myeloma

Activity Faculty

Paul G. Richardson, MD—Program Chair

Associate Professor of Medicine
Harvard Medical School
Clinical Director, Jerome Lipper Center for Multiple Myeloma
Dana-Farber Cancer Institute
Boston, Massachusetts

Thierry Facon, MD

Professor of Hematology
Service des Maladies du Sang
University of Lille
Lille, France

Sergio A. Giralt, MD

Chief, Adult Bone Marrow Transplant Service
Division of Hematologic Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Keith Stewart, MB ChB, MRCP, FRCPC, MBA

Dean for Research, Mayo Clinic in Arizona
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Mayo Clinic
Scottsdale, Arizona

Evangelos Terpos, MD, PhD

Assistant Professor of Hematology
Department of Clinical Therapeutics
University of Athens School of Medicine
Alexandra General Hospital
Athens, Greece

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine, Curatio CME Institute, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Podcast available at curatiocme.com

Credit Designation

Penn State College of Medicine designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in this CME activity. To receive credit during the period February 2011 to February 29, 2012, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the posttest and activity evaluation form, including the certificate information section.

To obtain a certificate, participants must receive a score of 70% or better on the posttest. The posttest can be accessed at the end of the activity. Please e-mail any questions to cmeinfo@curatiocme.com.

Medium

The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.

Disclosure

In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Thierry Facon, MD, has disclosed the following relevant financial relationships:

Advisory Board/Speaker Celgene, Janssen-Cilag
Advisor Bristol-Myers Squibb

Sergio A. Giralt, MD, has disclosed the following relevant financial relationships:

Advisory Board/Speaker Celgene, Genzyme, Millennium: The Takeda Oncology Company, Novartis
Dr. Giralt will discuss the unlabeled or investigational use of a commercial product.

Paul G. Richardson, MD, has disclosed the following relevant financial relationships:

Advisory Board Celgene, Johnson & Johnson, Millennium: The Takeda Oncology Company, Novartis

Dr. Richardson will discuss the unlabeled or investigational use of a commercial product.

Keith Stewart, MB ChB, MRCP, FRCPC, MBA, has disclosed the following relevant financial relationships:

Consultant Celgene, Millennium: The Takeda Oncology Company, Onyx

Dr. Stewart will discuss the unlabeled or investigational use of a commercial product.

Evangelos Terpos, MD, PhD, has disclosed the following relevant financial relationships:

Consultant Amgen, Janssen-Cilag, Novartis

Speaker Janssen-Cilag, Novartis

Dr. Terpos will discuss the unlabeled or investigational use of a commercial product.

Podcast available at curatiocme.com

Curatio CME Institute

Thomas Finnegan, PhD, Associate Medical Director, Curatio CME Institute, has disclosed no relevant financial relationships.

Denise C. LaTemple, PhD, President, Curatio CME Institute, has disclosed no relevant financial relationships.

Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation

Anne Quinn Young, MPH, Vice President, Communications, has disclosed no relevant financial relationships.

Penn State College of Medicine

Penn State faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Disclaimer

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, Penn State College of Medicine, the MMRF, Bristol-Myers Squibb, Celgene, Centocor Ortho Biotech, Lilly, Millennium: The Takeda Oncology Company, Novartis, and Onyx Pharmaceuticals do not recommend the use of any agent outside the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, Penn State College of Medicine, the MMRF, Bristol-Myers Squibb, Celgene, Centocor Ortho Biotech, Lilly, Millennium: The Takeda Oncology Company, Novartis, and Onyx Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Generic Name	Trade Name	Approved Use (if any)	Unapproved/ Investigational Use
Bendamustine	Treanda	Treatment of patients with chronic lymphocytic leukemia; treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen	Treatment of multiple myeloma (MM)
Bortezomib	Velcade	Treatment of patients with MM	Maintenance therapy; MM bone disease
Carfilzomib	NA	NA	Treatment of MM
Denosumab	Prolia	Treatment of postmenopausal women with osteoporosis at high risk for fracture	MM bone disease
Elotuzumab	NA	NA	Treatment of MM

Everolimus	Afinitor	Treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib	Treatment of MM
Lenalidomide	Revlimid	Treatment of MM, in combination with dexamethasone, in patients who have received at least one prior therapy	Frontline therapy; maintenance therapy; MM bone disease
Perifosine	NA	NA	Treatment of MM
Pomalidomide	NA	NA	Treatment of MM
Temsirolimus	Torisel	Treatment of advanced renal cell carcinoma	Treatment of MM
Thalidomide	Thalomid	Treatment of patients with newly diagnosed MM in combination with dexamethasone	Relapsed/refractory MM; frontline therapy in combination with melphalan-prednisone; maintenance therapy
Zoledronic acid	Zometa	Treatment of hypercalcemia of malignancy; patients with MM and patients with documented metastases from solid tumors, in conjunction with standard antineoplastic therapy	Treatment of MM

Policy on Privacy and Confidentiality

Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.

Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.

